|
1) Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: Improving global outcomes. Kidney Int. 2004; 66: 1310-4
|
|
|
|
2) Williams ME. Diabetic Nephropathy: The proterinuria hypothesis. Am J Nephrol. 2005; 25: 77-94
|
|
|
|
|
|
3) 富野康日己. 厚生省特定疾患進行性腎障害に関する調査研究班: IgA腎症分科会. IgA腎症治療指針. 日本腎臓学会誌. 2002; 44: 673-9
|
|
|
|
|
4) Usui J, Yamagata K, Kai H, et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Internal Med. 2001; 40: 697-702
|
|
|
|
|
|
5) Iseki K, Ikemiya Y, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003; 63: 1468-74
|
|
|
|
|
|
6) Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2, 089 apparently healthy individuals: a 4. 4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kid Dis. 2003; 42: 466-73
|
|
|
|
|
|
7) Klausen K, Borch JK, Feldt RB, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hyper-tension, and diabetes. Circulation. 2004; 110: 32-5
|
|
|
|
|
|
8) Irie F, Iso H, Fukasawa H, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006; 69: 1264-71
|
|
|
|
|
|
9) Hotta O, Miyazaki M, Furuta T. et al. Tonsil-lectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001; 38: 736-43
|
|
|
|
|
|
10) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet. 1997; 9069: 1857-63
|
|
|
|
|
|
11) de Zeeuw D, Remuzzi G, Parving HH, et al. RENNAL STUDY(Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan). Kidney Int. 2004; 65: 2309-20
|
|
|
|
|
|
12) Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardio-vascular events in subjects with micro-albuminuria. Circulation. 2004; 110: 2809-16
|
|
|
|
|
|
13) Boulware LE, Jaar BG, Tarvercarr ME, et al. Screening for proteinuria in US adults. JAMA. 2003; 290: 3101-14
|
|
|
|
|
|
14) Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and non-diabetic individuals: the Framingham Heart Study. Circulation. 2005; 112: 969-75
|
|
|
|
|
|
15) Grag AX, Kiberd BA, Clark WF, et al. Albumin-uria and renal insufficiency prevalence guides population screening: results from NHANES III. Kidney Int. 2002; 61: 2165-75
|
|
|
|
|
|
16) Woodhandler S, Pels RJ, Bor DH, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA. 1989; 262: 1214-9
|
|
|
|
|
|
17) Yamagata K, Takahashi H, Tomida C, et al. Prognosis of asymptomatic hematuria and/or proteinuria in men. Nephron. 2002; 91: 34-42
|
|
|
|
|
|
18) Koyama A, Igarashi M, Kobayashi M, et al. Natural history and risk factors for immuno-globulin a nephropathy. Am J Kid Dis. 1997; 29: 526-32
|
|
|
|
|
|
19) Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007; 71: 159-66
|
|
|
|
|
|
20) de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol. 2006; 17: 2120-6
|
|
|
|
|
|
21) Ninomiya T, Kiyohara Y, Kubo M, et al. Meta-bolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006; 48: 383-91
|
|
|
|
|
|
22) Tanaka H, Shiohara Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006; 69: 369-74
|
|
|
|
|